Medicines and Healthcare Products Regulatory Authority.
UKPAR Seroquel XL 50mg, 200mg, 300mg & 400mg prolonged-release tablets.
Srisurapanont, M, Maneeton, B, Maneeton, N. Quetiapine for schizophrenia. Cochrane Database Syst Rev
2004; 2: CD000967.
Leucht, S, Arbter, D, Engel, RR, Kissling, W, Davis, JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry
2009; 14: 429–47.
Hamer, RM, Simpson, PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry
2009; 166: 639–41.
Hutton, P, Morrison, AP, Yung, AR, Taylor, PJ, French, P, Dunn, G. Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. Acta Psychiatr Scand
2012; 126: 1–11.
Xia, J, Adams, C, Bhagat, N, Bhagat, V, Bhoopathi, P, El-Sayeh, H, et al. Losing participants before the end of the trial erodes credibility of findings. Psychiatr Bull
2009; 33: 254–7.
Leucht, S, Heres, S, Hamann, J, Kane, JM. Methodological issues in current antipsychotic drug trials. Schizophr Bull
2008; 34: 275–85.
Rabinowitz, J, Davidov, O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull
2008; 34: 286–91.
Leucht, S, Kane, JM, Etschel, E, Kissling, W, Hamann, J, Engel, RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology
2006; 31: 2318–25.
Thwin, SS, Hermes, E, Lew, R, Barnett, P, Liang, M, Valley, D, et al. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures. Psychiatry Res
2013; 209: 291–6.
Hermes, ED, Sokoloff, D, Stroup, TS, Rosenheck, RA. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry
2012; 73: 526–32.
Ebrahim, S, Akl, EA, Mustafa, RA, Sun, X, Walter, SD, Heels-Ansdell, D, et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. J Clin Epidemiol
2013; 66: 1014–21, .
Leucht, S, Kane, JM, Kissling, W, Hamann, J, Etschel, E, Engel, RR. What does the PANSS mean?
2005; 79: 231–8.
Furukawa, TA, Cipriani, A, Barbui, C, Brambilla, P, Watanabe, N. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol
2005; 20: 49–52.
Higgins, JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions.
Cochrane Collaboration, 2011.
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet
2009; 373: 31–41.
Gardner, DM, Murphy, AL, O'Donnell, H, Centorrino, F, Baldessarini, RJ. International consensus study of antipsychotic dosing. Am J Psychiatry
2010; 167: 686–93.
Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet
2013; 382: 951–62.
Leucht, S, Rothe, P, Davis, JM, Engel, RR. Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol
2013; 23: 956–9.
National Institute for Health and Clinical Excellence.
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary Care and Secondary Care (Update).
Bagnall, AM, Jones, L, Ginnelly, L, Lewis, R, Glanville, J, Gilbody, S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess
2003; 7: 1–193.
Jaeschke, R, Singer, J, Guyatt, GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials
1989; 10: 407–15.
Schennach-Wolff, R, Obermeier, M, Seemuller, F, Jager, M, Schmauss, M, Laux, G, et al. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. J Clin Psychopharmacol
2010; 30: 726–31.
Man-Son-Hing, M, Laupacis, A, O'Rourke, K, Molnar, FJ, Mahon, J, Chan, KB, et al. Determination of the clinical importance of study results. J Gen Intern Med
2002; 17: 469–76.
Guyatt, GH, Oxman, AD, Vist, GE, Kunz, R, Falck-Ytter, Y, Alonso-Coello, P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ
2008; 336: 924–6.
Leucht, S, Davis, JM, Engel, RR, Kissling, W, Kane, JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl
2009; 438: 7–14.
Samara, MT, Spineli, LM, Furukawa, TA, Engel, RR, Davis, JM, Salanti, G, et al. Imputation of response rates from means and standard deviations in schizophrenia. Schizophr Res
2013; 151: 209–14.
Harbord, RM, Higgins, JPT. Meta-regression in STATA. Stata J
2008; 8: 493–519.
Synopsis – Study 11915A: a one-year multi-national, multi-centre, randomised, double-blind, parallel-group, fixed-dose bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. Lundbeck, 2010.
Synopsis – Study 11916A: a one-year multi-national, multi-centre, randomised, double-blind, parallel-group, fixed-dose bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. Lundbeck, 2010.
Arvanitis, L, Scott, M. A multicenter, double blind, randomized, controlled, multiple fixed dose and dose regimen comparison of SEROQUELTM (ICI 204,636) and haloperidol in the prevention of psychotic relapse in outpatients with chronic or subchronic schizophrenia (5077IL/0015). AstraZeneca,1996.
Perlis, RH, Ostacher, M, Fava, M, Nierenberg, AA, Sachs, GS, Rosenbaum, JF. Assuring that double-blind is blind. Am J Psychiatry
2010; 167: 250–2.
Treadwell, JR, Uhl, S, Tipton, K, Shamliyan, T, Viswanathan, M, Berkman, ND, et al. Assessing equivalence and noninferiority. J Clin Epidemiol
2012; 65: 1144–9.
Spielmans, GI, Parry, PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. J Bioeth Inq
2010; 7: 13–29.
Potkin, SG, Gharabawi, GM, Greenspan, AJ, Mahmoud, R, Kosik-Gonzalez, C, Rupnow, MF, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res
2006; 85: 254–65.
Canuso, CM, Dirks, B, Carothers, J, Kosik-Gonzalez, C, Bossie, CA, Zhu, Y, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry
2009; 166: 691–701.
Arvanitis, LA, Miller, BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry
1997; 42: 233–46.
Lindenmayer, JP, Brown, D, Liu, S, Brecher, M, Meulien, D. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull
2008; 41: 11–35.
Findling, RL, McKenna, K, Earley, WR, Stankowski, J, Pathak, S. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol
2012; 22: 327–42.
Small, JG, Hirsch, SR, Arvanitis, LA, Miller, BG, Link, CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry
1997; 54: 549–57.
Borison, RL, Arvanitis, LA, Miller, BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol
1996; 16: 158–69.
Kahn, RS, Schulz, SC, Palazov, VD, Reyes, EB, Brecher, M, Svensson, O, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry
2007; 68: 832–42.
Cutler, AJ, Tran-Johnson, T, Kalali, A, Astrom, M, Brecher, M, Meulien, D. A failed 6-week, randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. Psychopharmacol Bull
2010; 43: 37–69.
Chen, EY, Hui, CL, Lam, MM, Chiu, CP, Law, CW, Chung, DW, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ
2010; 341: c4024.
Agid, O, Siu, CO, Potkin, SG, Kapur, S, Watsky, E, Vanderburg, D, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970–2010. Am J Psychiatry
2013; 170: 1335–44.
Leucht, S, Heres, S, Davis, JM. Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle. Am J Psychiatry
2013; 170: 1232–4.
Mallinckrodt, CH, Zhang, L, Prucka, WR, Millen, BA. Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull
2010; 43: 53–72.
Hamann, J, Kissling, W, Leucht, S. How long do psychiatrists wait for response before they switch to another antipsychotic?
2007; 40: 149–54.
Wieseler, B, Kerekes, MF, Vervoelgyi, V, McGauran, N, Kaiser, T. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ
2012; 344: d8141.
Hough, DW, Natarajan, J, Vandebosch, A, Rossenu, S, Kramer, M, Eerdekens, M. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol
2011; 26: 25–34.
Chapel, S, Hutmacher, MM, Haig, G, Bockbrader, H, de Greef, R, Preskorn, SH, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol
2009; 49: 1297–308.